%0 Journal Article
%T Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.
%A Damaskos C
%A Psilopatis I
%A Garmpi A
%A Dimitroulis D
%A Nikolettos K
%A Vrettou K
%A Sarantis P
%A Koustas E
%A Kouraklis G
%A Antoniou EA
%A Karamouzis MV
%A Nikolettos N
%A Tsikouras P
%A Marinos G
%A Kontomanolis E
%A Kontzoglou K
%A Garmpis N
%J Cancers (Basel)
%V 16
%N 1
%D 2024 Jan 1
%M 38201636
%F 6.575
%R 10.3390/cancers16010209
%X <B>OBJECTIVE: </B>Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer.<BR><B>METHODS: </B>A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.<BR><B>RESULTS: </B>Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.<BR><B>CONCLUSIONS: </B>High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.